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ABSTRACT
Objective: Choosing among HIV medications involve
making trade-offs among various efﬁcacy, convenience,
resistance, and side-effect attributes. This study tested
the feasibility of using adaptive conjoint analysis (ACA)
to assess preferences (utilities) for HIV medication
attributes.
Methods: HIV individuals were recruited through news-
paper advertisements. Participants completed a compu-
terized ACA survey that assessed 12 attributes, including
side effects, regimen convenience, resistance, and efﬁcacy.
Literature on third-agent HIV drugs was used to identify
percentage risk and severity level descriptions for each
attribute. Based on the ACA-derived utilities, we assessed
the relative importance of the attributes by averaging
individually calculated importance and estimated the per-
centages that would prefer selected HIV medications over
others. To check validity of the ACA utilities, the survey
also had respondents choose among medications with dif-
ferent attribute proﬁles.
Results: The 35 respondents were primarily African
Americans (94%) and unemployed (54%). Of these, 28
(80%) provided consistent responses and were analyzed.
Of the 12 medication attributes evaluated, the risk of
developing resistance, regimen convenience, and the risk
of sleep disturbance had the greatest impact on prefer-
ences; each accounting for more than 8.5% of the varia-
tion in preferences. These were followed by risk of drug
failure (8.2%), cholesterol elevation (7.1%), diarrhea
(7.1%) and nausea (6.9%). The ACA utilities accurately
predicted patients’ actual medication choices 75% of the
time.
Conclusions: Adaptive conjoint analysis was successful in
predicting HIV treatment preferences under different med-
ication scenarios. Resistance, regimen convenience, and
sleep disturbance would likely make the most difference in
the perceived value of a third-agent HIV medication.
Keywords: conjoint, HIV therapy, NNRTI, protease
inhibitors.
Introduction
Incorporating patient preferences into treatment
decisions is an essential component of optimal
medical care [1,2]. With respect to human immuno-
deﬁciency virus (HIV) medications, physicians and
patients confront a myriad of available options,
and each medication choice involves making trade-
offs among various convenience, side effect, efﬁ-
cacy, and resistance attributes [3]. These choices
become even more complex given that differences
in attributes among new HIV medications may be
small, but may still be important from the patient’s
perspective. Moreover, the risk of experiencing cer-
tain side effects can vary from patient to patient.
To our knowledge, no study evaluating HIV
medication preferences has taken into account the
risks of experiencing certain attributes. Conjoint
analysis would be an applicable methodology for
this scenario. Conjoint analysis is an established
method of eliciting consumer preferences in market
research, and it is increasingly being applied to
assess health-care interventions [4,5]. It derives
preferences by asking respondents to choose be-
tween different products, thus simulating the way
people actually make choices when faced with mul-
tiple alternatives [6]. Resulting data include relative
preferences, known as utility weights, assigned to
speciﬁc product or medication attributes. The utili-
ties can be used to identify which attributes most
strongly drive patients’ treatment choices, and the
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sums of the attribute utilities that match to speciﬁc
medication proﬁles can be used to predict patient
preferences among various medications.
Although conjoint analysis has successfully been
applied in health care, there was uncertainty regard-
ing whether or not conjoint methodology would be
feasible for assessing attributes associated with HIV
medications due to their complexity and the various
levels of risks involved. Therefore, a pilot study was
performed to assess the feasibility of using this
approach in a small group of HIV-positive individ-
uals. The speciﬁc objective of the study was to
quantify the relative importance of new generation,
third-agent HIV drug attributes based on their
severity and levels of risk.
Methods
Study Design
This cross-sectional study assessed the preferences
of HIV-positive individuals for different attributes
associated with HIV medications using adaptive
conjoint analysis (ACA) methodology. Study partic-
ipants were recruited through newspaper advertise-
ments in two Washington DC based newspapers,
the Washington Post, and Washington Blade. Inclu-
sion criteria included: 1) HIV positive; 2) at least
18 years of age; and 3) willingness to travel to a
conference facility and complete a questionnaire in
English on a laptop computer. All participants were
compensated $75.00 for their time. The Essex Insti-
tutional Review Board (Lebanon, NJ) approved the
study protocol.
Survey
The survey was computer-administered and
included four sections: 1) thermometer scale; 2)
ACA questions; 3) medication choice questions; and
4) demographic and clinical characteristics. The
ﬁrst section, which contained the thermometer
scale, was used to help familiarize the respondents
with the notion of ranking and to obtain rankings
of various medications attributes irrespective of
their risk of occurrence. Respondents were asked
to rank the importance of 16 different medication
attributes on a vertical scale from 0.0 (attribute
respondent cares about the least) to 100 (attribute
respondent cares about the most). The attributes
included selected side effects, efﬁcacy, developing
drug resistance, and regimen characteristics.
The second section, the ACA section, was used to
estimate the relative utilities, or preferences, associ-
ated with selected medication attributes. The
attributes in this section included those that had
been previously identiﬁed in the literature as key
factors inﬂuencing HIV medication preferences:
side effects, medication failure, developing drug
resistance, and regimen convenience [7,8]. ACA
assumes that each attribute is deﬁned by various
levels, which refer to a range of plausible estimates
for each attribute. For example, the levels for the
diarrhea side-effect attribute used in this study
were: 1) 1% chance (1 out of 100 people) of having
moderate to severe diarrhea involving ﬁve or more
loose stools per day; 2) 8% chance (8 out of 100
people) of having moderate to severe diarrhea
(involving ﬁve or more loose stools per day); and 3)
16% chance (16 out of 100 people) of having mod-
erate to severe diarrhea involving ﬁve or more loose
stools per day.
The attributes were written using lay terminol-
ogy and were adapted from clinical adverse event
severity descriptions and physician input. The levels
for each attribute, except the regimen convenience
attribute, described the risk of occurrence. The reg-
imen convenience attribute levels were presented
graphically (Appendix A, Exhibit 1) and matched to
those corresponding to the following HIV medica-
tions: fosamprenavir/ritonavir, fosamprenavir, lopi-
navir/ritonavir, nelﬁnavir, atazanavir, and efavirenz
(medication names were not provided in the
survey).
The ACA section involved three sets of questions.
First, respondents were asked to rank how accept-
able the levels were for each attribute. Second,
respondents were asked to rate the importance of
the difference between the highest and lowest levels
of each attribute on a seven-point scale. Finally,
respondents were asked a set of questions asking
them to choose one option from a pair called paired
comparisons. Speciﬁcally, two medications with
different attribute levels are presented, and the
respondents are asked which one they would prefer
on a seven-point Likert scale, ranging from
“Strongly prefer Drug A” to “Strongly prefer Drug
B.” ACA chooses pairs of options with similar ini-
tial utilities for which it expects respondents to be
indifferent based on previous responses. The pro-
gram is interactive and uses the information
obtained from each paired comparison to update
the estimates of each respondent’s utilities and to
select the next pair of options [9].
The next section of the survey was used to eval-
uate the consistency between the ACA-generated
utilities and actual medication choices. It included
ﬁve questions, each of which presented two medi-
cation proﬁles listing all attribute levels associated
with actual HIV medications, and the respondent
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was  asked  to  choose  the  medication  proﬁle  that
he  or  she  would  prefer.  The  questions  included
the drug proﬁles for the following comparators
(actual medication names were not provided): 1)
fosamprenavir/ritonovir versus lopinavir/ritonovir,
2) fosamprenavir/ritonovir versus efavirenz, 3)
fosamprenavir versus nelﬁnavir, 4) fosamprenavir
versus atazanavir, and 5) lopinavir/ritonavir versus
atazanavir. The attribute levels that were included
for each comparator medication are reported in
Appendix A, Exhibit 2 (regimen convenience
attributes appear in Exhibit 1, Appendix A). The
risk levels were primarily identiﬁed from pivotal
studies of the comparator therapies and package
insert information reporting moderate to severe side
effects in treatment-naive HIV populations [10–14].
Virologic failure was deﬁned as having a viral load
increase above 400 copies of HIV RNA/ml or fail-
ure to achieve viral suppression below 400 copies
HIV RNA/ml by end of study. For some attributes,
such as cholesterol elevation and drug resistance,
ﬁndings were not consistently reported and there-
fore the levels for these attributes are described
qualitatively based on input from clinical experts
(e.g., high chance, moderate chance, very low
chance).
Analysis
Descriptive statistics, such as means and percent-
ages, were used to characterize the sample demo-
graphics. Median values were reported for the
thermometer scale given that the distributions of
rankings were skewed.
For each participant, the ACA program (2003,
ACA Version 3.5, Sawtooth Software, Inc., Sequim,
WA) generated utility values for every level of each
attribute included in the survey. This was an itera-
tive process in which each respondent began with
an initial set of attribute level utilities based on their
answers to the ﬁrst set of acceptability questions.
Next, these initial utilities were reﬁned based on the
responses to the set of attribute importance ques-
tions so that the range of utility values within each
attribute was proportional to the stated importance.
Finally, based on the responses to the paired com-
parison questions, ordinary least squares regression
was used to calculate a ﬁnal set of utility values for
the attribute levels [9]. The resulting utilities were
rescaled so that the least preferable level within each
attribute was assigned 0.0. The median utility val-
ues were reported given that the distributions of the
utilities were skewed.
Next, the relative importance, expressed as a per-
centage, of each of the attributes in inﬂuencing
treatment decisions was calculated for each partic-
ipant by dividing the range of each attribute (utility
of highest level—utility of lowest level) by the sum
of ranges of all attributes, and multiplying it by 100
[9]. After calculating percent importance estimates
at the individual level, the median values of the
importance estimates across all participants were
reported given that the distributions were skewed.
Finally,  we  assessed  the  consistency  between
the ACA-generated utilities and actual medication
choices. Speciﬁcally, for each of the ﬁve questions
comparing two HIV medication proﬁles, we pre-
dicted the one each participant would choose based
on his or her utilities, and we then compared these
predictions with the actual choices made by the par-
ticipants. We predicted which medication a partici-
pant would choose by adding up his or her utilities
for each medication attribute level and identifying
the medication proﬁle with the highest sum, which
indicated greater preference. Some of the attributes
appearing in the ACA section of the survey did not
match directly to those that were used in the ﬁve
questions comparing two medication proﬁles. The
utilities for these attributes appearing in the medi-
cation proﬁles were estimated through linear inter-
polation of the ACA-derived utilities.
Results
Study Population
A total of 42 individuals were recruited to partici-
pate in the pilot study. Of these, 35 (83%) were able
to successfully complete the computer survey, which
took approximately 30 minutes. Most of those
who did not complete the survey were unfamiliar
with computers and had problems with the compu-
ter-administration. The sample was primarily male
(69%), African Americans (94%), and unemployed/
disabled (54%). The average time since patients
received a diagnosis of HIV was 11 years; 31%
became HIV positive from homosexual contact,
37% became HIV positive from heterosexual con-
tact, and 31% were positive from IV drug use or
other reasons. More than one-half (54%) of the
participants had only a high school education and
14% had completed college. Of the 35 participants,
26 were taking HIV medications and nine were
treatment-naive.
Thermometer Rankings
On the thermometer scale, in which the medication
attributes were described without a corresponding
risk of occurrence, the participants rated “Rash
with red blistering bumps that may involve your
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eyes, mouth, or private parts” (median = 90),
“Developing resistance [this or other HIV medica-
tion not working well or not at all] and limiting
future treatment options” (median = 85), and “The
medication failing or not working within 1 years”
(median = 81) as features that they cared about the
most. They rated “Not being able to take at the
same time as other HIV medications” (median =
45), “Food requirements or restrictions when tak-
ing the medication” (median = 45), and “Increasing
your cholesterol” (median = 40) as features they
cared about the least.
ACA Utilities
We reviewed individual responses to the conjoint
section questions and determined that seven partic-
ipants should be excluded from the ACA analyses
because of illogic answers. Speciﬁcally, in the ﬁrst
section of the ACA survey, these participants indi-
cated that a higher risk of experiencing a side effect
was more acceptable than a lower risk.
Table 1 reports the median utility values for each
attribute level for the 28 participants included in the
ACA analysis. Higher utility values indicate greater
preference; however, in comparing utilities across
attributes, pertinent information is found in the rel-
ative differences between the utilities and not their
absolute values [9]. For example, the participants
value a 5% reduced risk of moderate to severe
depression (increase of 40 utility units) more than a
6% reduced risk of moderate to severe jaundice
(increase of 36 utility units). Reducing the risk of
virologic failure from 15% to 7% (increase of 24
utility units) was considered approximately as
important as changing from a moderate chance to
a very low chance of developing drug resistance
(increase of 23 utility units).
Relative Importance of Attributes
Table 2 reports the median “percent importance”
estimates for each attribute. These estimates indi-
cate how much difference each attribute could make
in the total utility of an HIV medication. They
reﬂect the extent to which the difference in impor-
tance between the best and worst levels of each
attribute drives the decision to choose an HIV med-
ication. Variation in the risk of drug resistance had
the greatest impact on choice, accounting for
approximately 10% of the total relative impor-
tance. Variations in medication resistance, regimen
convenience, sleep disturbance, and medication fail-
ure impacted preferences almost twice as much as
moderate to severe rash, moderate to severe jaun-
dice, and moderate to severe vomiting.
Table 1 Median adaptive conjoint analysis (ACA) utilities
for each attribute level*
Attribute and respective levels 
(general public description)
Median utility
(N = 28)
Moderate to severe diarrhea (involving ﬁve or more 
loose stools per day)
1% chance 38
8% chance 20
16% chance 0
Moderate to severe nausea (where you feel sick to 
your stomach most of the day)
5% chance 25
10% chance 10
14% chance 0
Moderate to severe vomiting (having vomiting four 
or more times a day)
2% chance 29
5% chance 16
7% chance 0
Moderate to severe rash (with red blistering bumps
that may involve your eyes, mouth, or private parts)
1% chance 37
5% chance 15
10% chance 0
Moderate to severe jaundice (yellowing of skin and 
eyes that is noticeable to others)
<1% chance 36
6% chance 0
Moderate to severe dizziness (affecting your 
balance)
<1% chance 31
3% chance 14
6% chance 0
Moderate to severe depression (where you feel 
extreme sadness and are unable to enjoy life)
<1% chance 40
5% chance 0
Moderate to severe sleep problems (include vivid 
and disturbing dreams or being unable to sleep)
<1% chance 49
10% chance 25
25% chance 0
Virologic failure (medication failing or not working 
within 1 year)
7% chance 49
15% chance 25
21% chance 0
Increasing cholesterol
Very low chance 35
Moderate chance 18
High chance 0
Chance of developing resistance (this or other HIV 
medication not working as well or at all) and of 
limiting future treatment options
Very low chance 42
Low chance 34
Moderate chance 19
High chance 0
Very high chance 2
Regimen convenience†
Fosamprenavir 26
Fosamprenavir/ritonavir 22
Efavirenz 18
Atazanavir 16
Nelﬁnavir 6
Lopinavir/ritonavir 0
*Single value for one attribute level should not be compared with single values
from another attribute. Instead, one should compare differences in values
within each attribute.
†Medication name not provided in survey.
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Consistency of ACA Utilities with Actual Medication 
Choices
Table 3 reports the percentages of participants who
chose each comparator medication proﬁle (medica-
tion names were not included in the survey) and the
percentages of these choices that were accurately
predicted by summing each participant’s utilities
corresponding to each medication proﬁle. The util-
ity-based calculations accurately predicted choices
from 61% to 89% of the time (mean = 75%
accuracy).
Discussion
This adaptive conjoint pilot study among HIV-pos-
itive individuals successfully elicited preferences for
various attributes that may be associated with HIV
medications. The preference ratings generated by
the ACA had face validity in that higher values
reﬂected more favorable risk proﬁles. An advantage
of including tasks that account for speciﬁc risks is
that they closely mirror the choices that individuals
with HIV have to make in reality. The study ﬁndings
suggest that ACA is a useful tool for evaluating
patient preferences with respect to HIV medications
and may enhance the medical decision-making
process.
The differences observed between the thermom-
eter scale, which omitted levels of risk, and the ACA
section, which accounted for risk, showed the
impact of introducing risk when making treatment
decisions. On the thermometer, the participants
ranked moderate to severe rash as the feature that
they would care about the most in selecting a new
HIV medication. Nevertheless, on considering the
trade-offs between different levels of risk, they iden-
tiﬁed medications resistance, regimen convenience,
sleep disturbance, and medication failure as the
attributes that likely would make the most differ-
ence in the perceived value of an HIV medication.
The ACA utilities obtained in this study were fur-
ther substantiated by the ﬁnding that they accu-
rately predicted actual HIV medication choices with
approximately 75% accuracy.
It should be noted that the relative importance
of the attributes depends on the speciﬁc levels
included. We believe that the attribute levels
included in this survey were reasonable approxima-
tions of the ranges observed among HIV agents
available to treatment-naive patients. Nevertheless,
an advantage of ACA methodology is that it allows
for sensitivity analyses such that speciﬁc attributes
can be varied within ranges relevant for individual
patients or speciﬁc patient subgroups, and the
impacts of these changes on preferences can be
evaluated [6].
Consistent with previous HIV medication con-
joint analyses [7], the participants in this study
rated attributes related to the regimen convenience
(e.g., dosing frequency, pill burden) among the low-
est in importance when they were considered sepa-
rately on the thermometer scale. Nevertheless, the
participants rated the regimen convenience attribute
that combined various convenience features as one
of the most important attributes based on the con-
joint utilities. This ﬁnding suggests that the impor-
tance of each convenience feature is dependent on
how they are combined and that the overall treat-
ment regimen may have a substantial impact on the
patient’s life. As observed in a previous conjoint
study of HIV medications, the balance of conven-
ience attributes mattered more to patients than the
individual attributes alone [15].
Table 2 Median percent importance ratings for attributes*
Attribute All (N = 28)
Medication resistance 10.3% [1]
Regimen convenience 8.7% [2]
Sleep disturbances 8.6% [3]
Drug failure 8.2% [4]
Cholesterol elevation 7.1% [5]
Diarrhea 7.1% [5]
Nausea 6.9% [6]
Dizziness 5.8% [7]
Depression 5.5% [8]
Rash 5.0% [9]
Jaundice 4.7% [10]
Vomiting 4.7% [10]
*Ratings reﬂect the average of the individually calculated importances. For each
individual, the range of each attribute (utility of highest level—utility of lowest
level) was divided by the sum of ranges of all attributes, and multiplying by 100.
Table 3 Consistency of predicted choices to actual choices
Comparators
Actual choices
(N = 28)
% choosing 
medication
Percentage of choices
predicted accurately
using adaptive 
conjoint utilities
Fosamprenavir/ritonavir
vs.
Lopinavir/ritonavir
25 (89%)
vs.
3 (11%)
71
Fosamprenavir/ritonavir
vs.
Efavirenz
24 (86%)
vs.
4 (14%)
89
Fosamprenavir
vs.
Nelﬁnavir
24 (86%)
vs.
4 (14%)
86
Fosamprenavir
vs.
Atazanavir
21 (75%)
vs.
7 (25%)
70
Lopinavir/ritonavir
vs.
Atazanavir
18 (64%)
vs.
10 (36%)
61
Mean accuracy of 
utility-based predictions
75
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An advantage of this study is that it showed that
an ACA survey was feasible in a primarily African
Americans and less educated segment of the HIV
population. This expands on previous ACA studies
that have largely been comprised of white and rel-
atively well-educated participants [6,16,17]. These
ﬁndings are particularly important because low
ﬁnancial status has been found to be associated with
low adherence to HIV therapy, and therefore, ACA
may be a useful tool for estimating preferences, and
potentially enhancing treatment decisions, in such
populations [15].
This study has several limitations. Mild side
effects were not considered because they have not
uniformly been reported in the HIV treatment liter-
ature. Nevertheless, previous conjoint research
suggests that patients place greater importance on
serious side effects than mild effects even when the
probability of experiencing the serious side effects is
extremely small [18]. In addition, consistent with
previous conjoint studies in health care [6,7,16,18],
duration of side effects was not considered because
this would have greatly increased the complexity of
the attribute descriptions. Nevertheless, it is likely
that duration may not have substantially inﬂuenced
patient preferences given that the moderate to
severe side effects that were included in this study
frequently can cause action to be taken, such as
lowering a dose, switching medication, or hospital-
ization, irrespective of the duration of the event.
Also, this study did not include lipodystrophy, a vis-
ible side effect that may have substantial detrimen-
tal impact on patients, because published data on
lipodystrophy are not directly comparable among
HIV medications. Nevertheless, we do plan to
address lipodystrophy in a larger, follow-on study.
Another limitation of this study was that it relied
only on computer administration; some participants
had difﬁculty completing the survey because of their
lack of experience with computers. In addition,
20% of the participants provided inconsistent
answers on the conjoint survey and were excluded
from the generation of ACA utilities. Data on con-
joint survey inconsistency rates for comparison pur-
poses are lacking. Nevertheless, an inconsistency
rate of 9% was observed in a previous Internet-
based utility assessment in which 91% of the study
participants had at least some college education
[19]. Finally, we note that we used an information-
free criterion, random choice, as a benchmark for
assessing the accuracy of the predicted choices from
the adaptive conjoint utilities, and this may have
increased the likelihood of showing favorable ﬁnd-
ings. If a different benchmark was used, such as the
average frequency with which the dominant option
was chosen among the ﬁve choice sets, it would
appear that the ACA utilities may not contribute as
much additional information in determining medi-
cation decisions.
In conclusion, ACA was successful in evaluating
the trade-offs that individuals are willing to make
among HIV medication attributes and predicting
treatment preferences under different medication
scenarios. The ﬁndings from this pilot study suggest
that medication resistance, regimen complexity, risk
of sleep disturbance and medication failure would
likely make the most difference in the perceived
value of an HIV medication. ACA appears to be a
useful tool for incorporating patient preferences
into the HIV medication selection process. This
application will be used in a follow-on study to
assess HIV patient preferences in a larger study
population.
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Exhibit 1 Attribute levels for regimen convenience attribute.
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Exhibit 2* Assigned proﬁles for comparator medications
Attribute
Fosamprenavir/
rotinavir (%)
Fosamprenavir
(%)
Lopinavir/
rotinavir (%)
Nelﬁnavir
(%)
Atazanavir
(%)
Efavirenz 
(%)
Moderate to severe diarrhea 9 5 16 16 1 2
Moderate to severe nausea 7 5 7 5 14 13
Moderate to severe vomiting 6 2 3 4 4 7
Moderate to severe rash 2 7 1 2 6 10
Moderate to severe jaundice <1 <1 <1 <1 6 <1
Moderate to severe dizziness 1 <1 <1 <1 2 6
Moderate to severe depression <1 <1 <1 <1 4 5
Moderate to severe sleep problems <1 2 <1 2 <1 25
Virologic failure 7 14 13 17 20 21
Chance of increasing your cholesterol High chance High chance High chance High chance Very low chance Moderate chance
Chance of developing resistance Very low 
chance
High chance Very low 
chance
Moderate 
chance
High chance Very high chance
*Risks of occurrence based on studies of treatment-naive HIV patients.
The utilities for all assigned percentages not matching to those in survey were estimated using linear interpolation of observed values.
